Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination 英文参考文献.docVIP

Responseto2009PandemicInfluenzaA(H1N1)Vaccine inHIV-InfectedPatientsandtheInfluenceofPrior SeasonalInfluenzaVaccination DariusSoonawala1*,GuusF.Rimmelzwaan2,LucB.S.Gelinck3,LeoG.Visser1,FrankP.Kroon1 1 Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands, 2 Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands,3 Department of Internal Medicine, MC Haaglanden, the Hague, The Netherlands Abstract Background: The immunogenicity of 2009 pandemic influenza A(H1N1) (pH1N1) vaccines and the effect of previous influenza vaccination is a matter of current interest and debate. We measured the immune response to pH1N1 vaccine in HIV-infected patients and in healthy controls. In addition we tested whether recent vaccination with seasonal trivalent inactivated vaccine (TIV) induced cross-reactive antibodies to pH1N1. ( Identifier:NC MethodsandFindings: In this single-center prospective cohort study MF59-adjuvanted pH1N1 vaccine (FocetriaH, Novartis) was administered twice to 58 adult HIV-infected patients and 44 healthy controls in November 2009 (day 0 and day 21). Antibody responses were measured at baseline, day 21 and day 56 with hemagglutination-inhibition (HI) assay. The seroprotection rate (defined as HI titers$1:40) for HIV-infected patients was 88% after the first and 91% after the second vaccination. These rates were comparable to those in healthy controls. Post-vaccination GMT, a sensitive marker of the immune competence of a group, was lower in HIV-infected patients. We found a high seroprotection rate at baseline (31%). Seroprotective titers at baseline were much more common in those who had received 2009–2010 seasonal TIV three weeks prior to the first dose of pH1N1 vaccine. Using stored serum samples of 51 HIV-infected participants we measured